S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
ASX:NSB

NeuroScientific Biopharmaceuticals (NSB) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About NeuroScientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.


NSB Stock News Headlines

See More Headlines
Receive NSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroScientific Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.95 million
Book Value
A$0.03 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.63
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Abby Macnish Niven B.Com.
    B.Sc., C.F.A., CFO & Company Sec.
  • Mr. Stephen Carter
    Chief Exec. Officer
  • Dougal Thring
    Chief Operating Officer













NSB Stock - Frequently Asked Questions

What is NeuroScientific Biopharmaceuticals' stock symbol?

NeuroScientific Biopharmaceuticals trades on the ASX under the ticker symbol "NSB."

How much money does NeuroScientific Biopharmaceuticals make?

NeuroScientific Biopharmaceuticals (ASX:NSB) has a market capitalization of $0.00 and generates $4.95 million in revenue each year. The company earns $-1,070,000.00 in net income (profit) each year or A($0.01) on an earnings per share basis.

How can I contact NeuroScientific Biopharmaceuticals?

NeuroScientific Biopharmaceuticals' mailing address is 85 Forrest Street, Suite 5, Cottesloe, WA 6011, Australia. The official website for the company is www.neuroscientific.com. The company can be reached via phone at 61 8 6382 1800.

This page (ASX:NSB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -